Across TCGA pan-cancer cohorts, RPS16P5 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of RPS16P5’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where RPS16P5 RNA is repressed in tumor relative to normal tissue. In most cancer types RPS16P5 is over-expressed in tumor, although a few such as THCA show the opposite, repressed pattern.

THCA, KIRC, and LUAD are the cancer types where RPS16P5 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in RPS16P5 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Female	II,III,IV	−0.450	<.001	11	view →
KIRC	All	III,IV	+0.103	.003	7	view →
LUAD	Male	III,IV	+0.453	.006	3	view →
CHOL	All	All	+0.138	.026	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: RPS16P5 RNA expression & survival · all RPS16P5 data types